19,256 Shares in CeriBell (NASDAQ:CBLL) Purchased by Bank of America Corp DE

Bank of America Corp DE bought a new stake in shares of CeriBell (NASDAQ:CBLL - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 19,256 shares of the company's stock, valued at approximately $498,000. Bank of America Corp DE owned 0.05% of CeriBell as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. FMR LLC acquired a new stake in shares of CeriBell during the 4th quarter worth approximately $128,120,000. ABG WTT Global Life Science Capital Partners GP Ltd acquired a new stake in shares of CeriBell during the 4th quarter worth approximately $28,160,000. RA Capital Management L.P. acquired a new stake in shares of CeriBell during the 4th quarter worth approximately $21,340,000. Vanguard Group Inc. acquired a new stake in shares of CeriBell during the 4th quarter worth approximately $18,015,000. Finally, Board of Trustees of The Leland Stanford Junior University acquired a new stake in shares of CeriBell during the 4th quarter worth approximately $16,143,000.

Wall Street Analysts Forecast Growth

CBLL has been the subject of several recent analyst reports. LADENBURG THALM/SH SH started coverage on shares of CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 price objective for the company. Canaccord Genuity Group reiterated a "buy" rating and issued a $33.00 target price on shares of CeriBell in a report on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $32.50.

Insider Buying and Selling at CeriBell

In other news, CEO Xingjuan Chao sold 25,000 shares of CeriBell stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $17.00, for a total transaction of $425,000.00. Following the sale, the chief executive officer now directly owns 776,022 shares in the company, valued at $13,192,374. The trade was a 3.12% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders have sold 74,700 shares of company stock worth $1,221,434. Corporate insiders own 20.10% of the company's stock.

CeriBell Price Performance

Shares of CBLL traded down $0.91 during trading hours on Friday, reaching $17.27. The stock had a trading volume of 406,345 shares, compared to its average volume of 280,154. CeriBell has a 12 month low of $10.01 and a 12 month high of $32.75. The firm has a 50-day simple moving average of $16.53 and a 200 day simple moving average of $21.08.

CeriBell (NASDAQ:CBLL - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.07. The company had revenue of $20.49 million for the quarter, compared to the consensus estimate of $19.30 million. Sell-side analysts anticipate that CeriBell will post -2.46 earnings per share for the current fiscal year.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.